Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vita Life SciencesASX:VLS +0.81%78 EV-to-OCF is 6.18 as of Jul. 16, 2026, which is 45% below its 10-year median of 11.22. GuruFocus rates ASX:VLS with a GF Score™ of 78/100 and a GF Value™ of A$2.49 (Fairly Valued). The stock has 1 warning sign investors should review. Among 1,008 Drug Manufacturers companies, Vita Life Sciences ranks better than 60.32% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Vita Life Sciences's Enterprise Value is A$101.58 Mil.
Vita Life Sciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was A$16.43 Mil. Therefore, Vita Life Sciences's EV-to-OCF for today is 6.18.
The historical rank and industry rank for Vita Life Sciences's EV-to-OCF or its related term are showing as below:
ASX:VLS'
s EV-to-OCF Range Over the Past 10 Years
Min: 4.06 Med: 11.22 Max: 29.56
Current: 6.25
During the past 13 years, the highest EV-to-OCF of Vita Life Sciences was 29.56. The lowest was 4.06. And the median was 11.22.
ASX:VLS's EV-to-OCF is ranked better than 60.32% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 10.725
vs ASX:VLS: 6.25
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Vita Life Sciences (ASX:VLS) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Vita Life Sciences's PE Ratio (TTM) for today is calculated as:
Vita Life Sciences's share price for today is A$2.48.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Vita Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.183.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Vita Life Sciences EV-to-OCF Related Terms
Vita Life Sciences EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Vita Life Sciences's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vita Life Sciences's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vita Life Sciences EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vita Life Sciences's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Vita Life Sciences's EV-to-OCF falls into.
Vita Life Sciences's current Enterprise Value is A$101.58 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Vita Life Sciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was A$16.43 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vita Life Sciences (ASX:VLS) has a EV-to-OCF of 6.18 as of Jul. 16, 2026. This is 45% below median its historical median of 11.22. Over the past decade, Vita Life Sciences' EV-to-OCF has ranged from 4.06 to 29.56. According to the industry distribution chart, Vita Life Sciences ranks #400 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 39.7%.
Is Vita Life Sciences' EV-to-OCF too high?
Vita Life Sciences' current EV-to-OCF of 6.18 is 45% below median its 10-year median of 11.22. Over the past 10 years, this metric has ranged from a low of 4.06 to a high of 29.56. The Drug Manufacturers industry median EV-to-OCF is 10.73. Vita Life Sciences' value of 6.18 is 42.4% below this industry median. Based on the distribution chart, Vita Life Sciences ranks #400 out of 1008 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Vita Life Sciences has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vita Life Sciences' EV-to-OCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vita Life Sciences ranks #400 out of 1008 companies for EV-to-OCF. This puts Vita Life Sciences in the upper half of its industry. The industry median EV-to-OCF is 10.73. Vita Life Sciences' value of 6.18 is 42.4% below this benchmark. Historically, Vita Life Sciences' own EV-to-OCF has ranged from 4.06 to 29.56 over the past decade. While the company's 10-year median is 11.22 vs. the industry median of 10.73, Vita Life Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.73, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vita Life Sciences's current EV-to-OCF of 6.18 is 42.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vita Life Sciences's current EV-to-OCF is 6.18, which is 45% below median its own 10-year median of 11.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vita Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Vita Life Sciences (ASX:VLS) is currently considered Fairly Valued. The stock's GF Value™ is A$2.49, compared to a current price of A$2.48 — trading 0.4% below its estimated fair value. The current EV-to-OCF is 6.18, which is 45% below median its 10-year median of 11.22 and 42.4% below the Drug Manufacturers industry median of 10.73. Vita Life Sciences' overall GF Score™ is 78/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Vita Life Sciences (ASX:VLS), the current EV-to-OCF is 6.18 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vita Life Sciences (ASX:VLS) Overvalued in 2026?
Based on GuruFocus' analysis, Vita Life Sciences stock appears to be undervalued.
The current stock price of A$2.48 is trading 0.4% below its estimated GF Value™ of A$2.49.
GuruFocus considers Vita Life Sciences to be Fairly Valued.
Key valuation signals for ASX:VLS:
EV-to-OCF: 6.18 (45% below median its 10-year median of 11.22)
GF Value™: A$2.49 vs. price of A$2.48 (0.4% below fair value)
Industry Position: 42.4% below the Drug Manufacturers median (#400 of 1008)
No single metric tells the full story. See the ASX:VLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vita Life Sciences Ltd is an Australian-based pharmaceutical and healthcare company involved in formulating, packaging, selling, and distributing vitamins and supplements. It produces a wide range of premium supplements, vitamins, minerals, herbs, and superfoods catered to all age categories and health conditions. The company markets its products through pharmacies and health food stores under the VitaHealth, VitaScience, and Herbs of Gold brands throughout the Asia-Pacific region. Vita Life Sciences has two operating segments: VMS Operational, which generates maximum revenue, and VMS Investments. Geographically, the Group generates maximum revenue from Malaysia and Singapore, and the rest from Australia, and China and Vietnam.
78GF Score
Get the complete analysis for ASX:VLS
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VLS has been successfully added to your 
